Personalised digital therapy to achieve and sustain alcohol abstinence

AlcoChange is the behavioural-change therapist in your pocket, observing behaviours, adapting to your preferences, and actively guiding you to achieve and sustain abstinence.

How it Works Enquire

90-dayPrescription programme

ClinicianDashboard oversight

OptionalDigital breathalyser

What is AlcoChange?

A UKCA-marked, Class IIa medical device prescribed by clinicians to support patients with alcohol-related liver disease

90-Day Programme

A structured treatment course delivered through a mobile application, prescribed by the treating clinician as an adjunct to standard clinical care for adults aged 18 or over with established ARLD.

Clinician Oversight

A web-based clinician dashboard presents behavioural-risk and engagement information, together with validated questionnaire outputs, enabling the supervising clinical team to monitor each patient's progress.

Behaviour Change Techniques

AlcoChange delivers behavioural change interventions based on the CyberLiver Behaviour Change (CBC) Model, using 34 personalised digital behaviour change techniques and over 150 behaviour change notifications.

Clinical Evidence

Findings from a peer-reviewed feasibility pilot, with a larger NIHR-funded randomised controlled trial ongoing

75.5%

Median reduction in self-reported alcohol use Per-patient change over 90 days (Wilcoxon p<0.01). Within-group descriptive statistic from an uncontrolled, single-arm pilot.

41/65

Completed the pilot programme Single-centre feasibility pilot at Royal Free London NHS Trust. 63.1% follow-up rate at three months (Mehta et al., JHEP Reports 2024).

324

Patients recruited to the RCT NIHR-funded, multi-centre RCT across 25 NHS Trusts (ISRCTN10911773). Primary endpoint at 180 days; results expected Q3 to Q4 2026.

Evidence basis: Feasibility pilot (n=41 completers of 65 enrolled), uncontrolled and single-arm; consumption reduction is a within-group descriptive statistic, not a treatment effect. All findings are being formally evaluated in the ongoing NIHR-funded RCT (ISRCTN10911773). AlcoChange does not claim to halt or reverse disease progression, reduce healthcare costs, or improve psychological wellbeing or mood.

Intended Use

AlcoChange is a prescription-only digital therapeutic intended to support the reduction of alcohol use and the maintenance of abstinence in adults (aged 18 years or over) with established alcohol-related liver disease (ARLD). It is used as an adjunct to standard clinical care, under the supervision of a qualified clinical team, and does not replace standard clinical care. AlcoChange delivers behavioural change interventions and provides information used by the clinical team to monitor the patient's behavioural risk (relapse and disengagement) during treatment.

View Full Information Materials

Interested in AlcoChange for your service?

AlcoChange is a prescription-only medical device. Get in touch to learn how it can support your hepatology or alcohol care service.